Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00402987 · ClinicalTrials.gov registry record · Phase 3

Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat

A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 3
Development phase
269
Enrollment target

NCT00402987 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 269 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00402987, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 3
Development phase
269 participants
Enrollment target

Study Summary

We are proposing a study in which we utilize and augment the sore throat pain model to assess the analgesic effectiveness of celecoxib compared to placebo in patients with painful pharyngitis under randomized, double-blind, placebo-controlled conditions.

Interventions

  • DRUG placebo
  • DRUG Celecoxib
  • DRUG celecoxib

Trial Details

FieldValue
Enrollment Target 269 participants
Start Date 2006-12-04
Est. Completion 2007-11-15
Phase Phase 3

What the Registry Record Tells You About NCT00402987

The ClinicalTrials.gov registry entry for NCT00402987 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT00402987 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00402987 about?

NCT00402987 is a clinical study titled "Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat". We are proposing a study in which we utilize and augment the sore throat pain model to assess the analgesic effectiveness of celecoxib compared to placebo in patients with painful pharyngitis under randomized, double-blind, placebo-controlled conditions.

What is the current status of trial NCT00402987?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 269 participants. The study started on 2006-12-04. Estimated completion is 2007-11-15.

What interventions are being tested in trial NCT00402987?

The interventions under investigation include: placebo (DRUG), Celecoxib (DRUG), celecoxib (DRUG).

Who is sponsoring clinical trial NCT00402987?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.